Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Sodium Metabisulfite for Calcinosis in Systemic Sclerosis
NCT06155578Phase 2Unknown
- Sponsor
- Pontificia Universidad Católica de Chile
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in calcinosis cutis comparing Sodium Metabisulfite with Placebo (2 arms). Primary endpoints: Safety and Tolerability (Adverse Events) at 4 months and Radiographic Progression of Calcinosis at 4 months. Status: unknown.
02
Drugs
sodium metabisulfite
03
Conditions
calcinosis cutis
Beyond the preview
Go deeper on NCT06155578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06155578.